about
Dietary supplements for chronic goutInterleukin-1 inhibitors for acute goutDietary supplements for chronic goutGout: optimizing treatment to achieve a disease cureLupus nephritis: a 15-year multi-centre experience in the UK.Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?Treatment target and followup measures for patients with gout: a systematic literature review.Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.Mechanisms of crystal formation in gout-a structural approach.Current advances in therapies for calcium pyrophosphate crystal arthritis.Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register.Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature.Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment.Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis.Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry.Primary tuberculosis infection in patients treated with tumor necrosis factor-alpha antagonists and a negative initial screening.Centre-related variability in hospital admissions of patients with spondyloarthritis.Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study.Clinical Images: Hematoidin in Synovial Fluid.Managing Gout in the Patient with Renal Impairment.Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.Severe gout: Strategies and innovations for effective management.Gout mimicking rheumatoid arthritis.Bruton's Tyrosine Kinase Inhibitors Could Induce Rheumatoid Arthritis-Like Manifestations: Comment on the Article by Nyhoff et al.Back pain due to lumbar gouty flare--a prospective diagnosis.Marked improvement of lung rheumatoid nodules after treatment with tocilizumabSmall muscle myositis in a patient with systemic lupus erythematosus successfully treated with rituximabMethotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritisNo hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximabAnakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutationLepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in SpainMRI myositis sine myositis: the importance of the histopathologyEffects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment MattersCriteria for gout diagnosis?Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective studyPigmented villonodular synovitis diagnostic delay due to coexistence with ankylosing spondylitisDealing with refractoriness in obstetric primary antiphospholipid syndrome--often not a matter of successInterleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report
P50
Q24193159-8EA213ED-519D-4991-B040-25986DBE66D8Q24193902-536B7189-29D0-49C3-8EBD-8958113DD951Q24197922-3F34B4D6-C2DD-4432-AC0A-4C66950DE4A6Q26765550-D5D45BA7-E6DD-432B-B8B8-C3CCAE32B4B1Q34578139-269EC5FD-7E52-4056-A398-2575CD170E55Q35232958-D10894C3-17A8-4721-8C8D-550BA39359F7Q35236585-6E20CE90-FCC2-48C3-889A-D8FD6166275AQ37553140-C9B34DEF-9740-4EEB-8E0B-0035FBCAF339Q38586640-E6050CED-8201-409B-94C0-9CBB20BD2594Q38701148-CF0D0654-459A-4B61-8CE8-4CD77C62E4D8Q38907911-F5B1C90F-F46F-47A3-B202-3CCD66CB068FQ39320712-B7AF54C2-137C-4F9A-83B0-6DF8C67F7E39Q40308633-9DCD415D-E6CD-4962-AF8B-E1E2412F8B19Q40378504-814C094A-7CB0-4025-9820-D1CAC04E5F57Q40395803-77C58DD6-BC82-464A-99DC-85385E096174Q40831626-E6A824B5-27D4-4108-A918-3380F83820A5Q41146273-D09DC639-6407-4F11-9A0E-6BD11193C302Q48177339-365E6B66-2939-4AC2-9010-55CC3D064FDDQ48209584-2A72E197-E53D-470F-9CDE-5CB7B86981A3Q48265903-2A199EC9-5A05-4557-B820-C906087B77A7Q48353144-89549F22-56F2-4E28-B13D-2D452C5EBC2FQ50050773-C27208DB-193C-4E02-A818-486B6381FB26Q51736512-54396255-1A7C-4114-B498-BE005E6B7C2FQ53641591-9BDC17EF-4D74-4726-817F-FFAC03518588Q53748495-2C08DC13-F2DB-4FE5-961D-86445A991300Q54170426-E2A824A2-605E-4B56-888E-AD6AB1041E07Q54363848-A464B95A-1600-44E6-A7ED-F884A46A04E7Q83430673-9CD5CDDD-6A9F-491A-9B01-53174AF2E002Q84570158-F4D3E3DA-8F18-49EF-AD7A-DB33B7CCF0D1Q84621367-B54B2FEF-93B2-4BA5-B59F-14CD4B712F24Q84636123-84E16360-7A81-43C3-B183-AF1E917A0795Q84782852-3DACED9C-B4FF-4A9E-B150-2C4C1DD9F71FQ84979953-2F12FBD6-6942-4AE5-A5C8-BA1F6E16AEDEQ85345765-4B2E89C6-A860-4A39-9302-9D00688ED8D4Q86032103-E0315C3B-81CC-4B1C-A467-E154DA9AFB21Q86520230-C9D01EB7-06BB-4432-8D5F-399582E58534Q87234573-FF48F876-A98D-41D5-9773-CBE37031E4EAQ87466619-21828D03-5B46-47D9-B91A-0E11639AEB0DQ87894773-20F96F3F-AD38-4B08-B61D-1CD9DE226C51Q88052792-B848D6F8-89EA-4631-AB6B-ED6055756169
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mariano Andrés
@ast
Mariano Andrés
@en
Mariano Andrés
@es
Mariano Andrés
@nl
Mariano Andrés
@sl
type
label
Mariano Andrés
@ast
Mariano Andrés
@en
Mariano Andrés
@es
Mariano Andrés
@nl
Mariano Andrés
@sl
prefLabel
Mariano Andrés
@ast
Mariano Andrés
@en
Mariano Andrés
@es
Mariano Andrés
@nl
Mariano Andrés
@sl
P1053
G-7708-2017
P106
P21
P31
P3829
P3835
mariano-andrs2
P496
0000-0002-0219-9055
P569
2000-01-01T00:00:00Z